AQSE: EDX
("EDX Medical" or the "Company")
Result of Annual General Meeting
The Annual General Meeting of
All 16 resolutions put to members were passed on a poll. Resolutions 1 to 13 were passed as ordinary resolutions and resolutions 14 to 16 were passed as special resolutions.
The number of votes cast for and against each of the resolutions proposed, and the number of votes withheld were as follows:
|
Resolution |
Votes for |
% |
Votes against |
% |
Votes withheld |
|
Resolution 1 (Ordinary) To receive the Annual Report and Accounts of the Company for the year ended |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
|
Resolution 2 (Ordinary) To accept the Remuneration Committee Report for the financial year ended |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
|
Resolution 3 (Ordinary) To accept the Directors' Remuneration Policy as set out in the Company's Annual Report and Accounts for the year ended |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
|
Resolution 4 (Ordinary) To re-appoint |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
|
Resolution 5 (Ordinary) To re-appoint Dr |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
|
Resolution 6 (Ordinary) To re-appoint Professor |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
|
Resolution 7 (Ordinary) To re-appoint Professor |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
|
Resolution 8 (Ordinary) To appoint |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
|
Resolution 9 (Ordinary) To re-appoint |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
|
Resolution 10 (Ordinary) To authorise the Directors to determine the fees payable to the auditor |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
|
Resolution 11 (Ordinary) To approve the EDX Medical Group Plc Non-Enterprise Management Incentive Plan |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
|
Resolution 12 (Ordinary) To approve the EDX Medical Group Plc Enterprise Management Incentive Plan |
179,018,268 |
99.99 |
16,666 |
0.01 |
16,000 |
|
Resolution 13 (Ordinary) To authorise the Directors to allot shares in the Company. |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
|
Resolution 14 (Special) To disapply statutory pre-emption rights generally. |
179,018,268 |
99.99 |
16,666 |
0.01 |
16,000 |
|
Resolution 15 (Special) To disapply statuatory pre-emption rights pursuant to an acquisition or other capital investment. |
179,018,268 |
99.99 |
16,666 |
0.01 |
16,000 |
|
Resolution 16 (Special) To authorise the Company to make market purchases. |
179,034,268 |
99.99 |
16,666 |
0.01 |
0 |
As at
The full text of each resolution is available in the Notice of Annual General Meeting, published on our website.
Contacts:
|
|
|
|
Dr (Chief Executive Officer) |
+44 (0)7812 345 301
|
|
|
|
|
|
|
|
|
+44 (0)20 3179 5300 |
|
|
|
|
IFC Advisory (Investor Relations)
|
+44 (0) 203 934 6630 |
|
|
+44 (0)7788 414856 + 44 (0)7834 694609 |
Notes to Editors:
EDX Medical Group Plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).
EDX Medical was founded by Professor Sir
By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.
EDX Medical provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the